A fast-track vaccine will be tried on people soon but it uses an unproven technology. During a press opportunity on March 2, a dozen biotech company executives joined President Donald Trump around the same wooden table where his cabinet meets. As each took a turn saying what they could add to the fight against the spreading
Mesoblast today announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. The Company is in active discussions with various government and regulatory authorities, medical institutions and pharmaceutical companies to
An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory illness COVID-19 yielded an estimate of 5.1 days for the median disease incubation period, according to a new study led by researchers at Johns Hopkins Bloomberg School of Public Health. This median time from exposure to onset of
This helps to explain the rapid and efficient way in which the virus has spread around the world. At the same time, the study suggests that while people with mild infections can still test positive by throat swabs for days and even weeks after their illness, those who are only mildly sick are likely not still infectious
The epidemiological features of the coronavirus disease 2019 (Covid-19) outbreak are described and evaluated the impact of non-pharmaceutical interventions on the epidemic in Wuhan, China. Individual-level data on 25,961 laboratory-confirmed Covid-19 cases reported through February 18, 2020 were extracted from the municipal Notifiable Disease Report System. Based on key events and interventions, the epidemic was
ISSCR has become aware of recent claims that stem cells can be used to treat people infected with COVID-19. While stem cell research shows promise for numerous diseases and conditions, there currently are no approved stem cell-based approaches for the prevention and treatment of COVID-19 infection. The ISSCR is a vocal and active opponent of the premature
Takeda Pharmaceutical Co said on Wednesday it was developing a drug for high-risk patients infected with the new coronavirus, joining several other drugmakers seeking to develop a treatment for an illness that has killed over 3,000 people. The Japanese firm said it was working on a plasma-derived therapy which had previously been shown to be
Forty-five people will be enrolled in the preliminary safety trial of the new vaccine. Researchers in Seattle have begun recruiting healthy volunteers to participate in a clinical trial for an experimental COVID-19 vaccine, according to news reports. The vaccine, developed by the biotechnology company Moderna Therapeutics, was initially sent to the National Institute of Allergy
A population of stem cells with the ability to generate new bone has been newly discovered by a group of researchers at the UConn School of Dental Medicine. In the journal STEM CELLS, lead investigator Dr. Ivo Kalajzic, professor of reconstructive sciences, postdoctoral fellows Dr. Sierra Root and Dr. Natalie Wee, and collaborators at Harvard, Maine
A person with a genetic condition that causes blindness has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial to test the ability of CRISPR–Cas9 gene-editing techniques to remove mutations that cause a rare condition called Leber’s congenital amaurosis 10 (LCA10).
